Are you Dr. Levis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 63 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-8964- Is this information wrong?
Summary
- Dr. Mark Levis, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland and District of Columbia. He is affiliated with Johns Hopkins Hospital and Sibley Memorial Hospital.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
- Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
- University of California San Francisco School of MedicineClass of 1994
Certifications & Licensure
- MD State Medical License 1997 - 2024
- DC State Medical License 2017 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 02
Publications & Presentations
PubMed
- 1 citationsSorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.Loo, S., Roberts, A., Anstee, N., Kennedy, G., He, S., Schwarer, A., Enjeti, A., D'Rozario, J., Marlton, P., Bilmon, I., Taper, J., Cull, G., Tiley, C., Verner, E., Ha...> ;Blood. 2023 Dec 7
- Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplan...Kayser, S., Sartor, C., Giglio, F., Bruno, A., Webster, J., Chiusolo, P., Saraceni, F., Guerzoni, S., Pochintesta, L., Borlenghi, E., Marconi, G., Zacheo, I., Cerrano,...> ;Haematologica. 2023 Dec 7
- 1 citationsGilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Jose Carlos Cruz, Tara L Lin, Gary J Schiller, Joseph G Jurcic, Adam Asch, Ruish...> ;Journal of Clinical Oncology. 2023 Sep 10
- Join now to see all
Press Mentions
- Improving Risk Stratification in Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia in ChildrenApril 21st, 2023
- AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”February 8th, 2023
- The Efficacy of ATO and ATRA for APLOctober 13th, 2021
- Join now to see all
Hospital Affiliations
- Johns Hopkins HospitalBaltimore, Maryland
- Sibley Memorial HospitalWashington, District of Columbia